



References: Clinical Considerations

METHYLPHENIDATE, AMPHETAMINES

1. Warren E et al. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry. *Can J Cardiol* 2009;25:625-630
2. CADDRA Canadian ADHD Resource Alliance. 2020 Canadian ADHD Practice Guidelines. Edition 4.1. <https://www.caddra.ca/>
3. National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. 2019. <https://www.nice.org.uk/guidance/ng87>
4. Cortese S. Pharmacologic Treatment of Attention Deficit Disorder. *N Engl J Med* 2020;383:1050-1056
5. Health Canada Drug Product Database. Ritalin/Ritalin SR.
6. Health Canada Drug Product Database. Concerta.
7. Health Canada Drug Product Database. Biphentin CR.
8. Health Canada Drug Product Database. Foquest.
9. Health Canada Drug Product Database. Dexedrine, Dexedrine Spansules.
10. Health Canada Drug product Database. Vyvanse.
11. Health Canada Drug product Database. Adderall XR.
12. US Food and Drug Administration Database. Ritalin, Ritalin SR.
13. US Food and Drug Administration Database. Ritalin LA.
14. US Food and Drug Administration Database. Concerta.
15. US Food and Drug Administration Database. Aptensio XR.
16. US Food and Drug Administration Database. Adhansia XR.
17. US Food and Drug Administration Database. Adderall XR.
18. US Food and Drug Administration Database. Dexedrine Spansule.
19. US Food and Drug Administration Database. Vyvanse.
20. Habel L et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA* 2011;306:2673-2683
21. Cooper O et al. ADHD drugs and serious cardiovascular events in children and young adults. *N Engl J Med* 2011;365:1896-1904
22. US Food and Drug Administration. Drug Safety Communication. Safety review update of medications used to treat ADHD in children and young adults. 2011. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention>
23. US Food and Drug Administration. Drug Safety Communication. Safety review update of medications used to treat ADHD in adults. 2011. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0>
24. CredibleMeds®. <https://www.crediblemeds.org/>
25. Health Canada. Summary Safety Review. Methylphenidate Priapism. 2015. <https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?linkID=SSR00032>
26. US Food and Drug Administration. Drug Safety Communication. Methylphenidate Priapism. 2013. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-rare-risk-long-lasting-erections-males-taking>
27. Pucci M et al. Drug-induced priapism. *Adverse Drug Reaction Bulletin*. June 2020.
28. Malkani M et al. Behavioral sleep interventions for children with ADHD: a systematic review and meta-analysis. *J Atten Disorders* 2022; June 25 [epub ahead of print]
29. Health Canada. Summary Safety Review. Methylphenidate Suicidal Thoughts and Behaviours (Suicidality). 2015. <https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?linkID=SSR00033>
30. Health Canada. Summary Safety Review. Amphetamines Suicidal Thoughts and Behaviours (Suicidality). 2015. <https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?linkID=SSR00034>
31. Pliszka S. ADHD and anxiety: clinical implications. *J Atten Disorders* 2019;23:203-205
32. Viktorin A et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. *Am J Psychiatry* 2017;174:341-348
33. Osland S et al. Pharmacological treatment for ADHD in children with comorbid tic disorders (Review). *Cochrane Database Syst Rev* 2018:CD007990
34. Cohen S et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. *J Am Acad Child Adolesc Psychiatry* 2015;54:728-736
35. BC Children's Hospital. Kelty Mental Health Resource Centre. Managing Stimulant Medication. April 2022. https://keltymentalhealth.ca/sites/default/files/resources/ManagingStimulantMedications_2022.pdf

36. Baweja R et al. Impact of CNS Stimulants for attention-deficit/hyperactivity disorder on growth: epidemiology and approaches to management in children and adolescents. *CNS Drugs* 2021;35:839-859
37. Greenhill L et al. Trajectories of growth associated with long-term stimulant medication in the Multimodal Treatment Study of Attention-Deficit Disorders. *J Am Acad Child Adolesc Psychiatry* 2020;59:978-989
38. Swanson J et al. Stimulant-related reductions of growth rates in the PATS (Preschool ADHD Treatment Study). *J Am Acad Child Adolesc Psychiatry* 2006;45:1304-1313
39. Swanson J et al. Effects of stimulant medication on growth rates across 3 Years in the MTA Follow-up. *J Am Acad Child Adolesc Psychiatry* 2007;46:1015-1027
40. Swanson J et al. Young adult outcomes in the follow-up of the multimodal treatment study of ADHD: symptom persistence, source discrepancy and height suppression. *J Child Psychol Psychiatry* 2017;58:663-678
41. Carucci et al, Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. *Neuroscience and Biobehavioral Reviews* 2021;120:509-525
42. Humphreys K et al. Stimulant medication and substance use outcomes: a meta-analysis. *JAMA Psychiatry* 2013;70:740-749
43. Wilens T et al. The impact of pharmacotherapy of childhood-onset psychiatric disorders on the development of substance use disorders. *J Child Adolesc Psychopharmacol* 2022;32:200-214
44. Faraone S et al. Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies. *J Am Acad Child Adolesc Psychiatry* 2020;50:100-112

ATOMOXETINE

1. Wolraich ML et al. American Academy of Pediatrics. Clinical Practice Guideline for the Diagnosis, Evaluation and Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents. *Pediatrics* 2019;144:e20192528
2. CADDRA Canadian ADHD Resource Alliance. 2020 Canadian ADHD Practice Guidelines. Edition 4.1. <https://www.caddra.ca/>
3. National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. 2019. <https://www.nice.org.uk/guidance/ng87>
4. Cortese S. Pharmacologic Treatment of Attention Deficit Disorder. *N Engl J Med* 2020;383:1050-1056
5. Health Canada Drug Product Database. Strattera.
6. US Food and Drug Administration Database. Strattera.
7. Habel L et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA* 2011;306:2673-2683
8. Cooper W et al. ADHD drugs and serious cardiovascular events in children and young adults. *N Engl J Med* 2011;365:1896-1904
9. US Food and Drug Administration. Drug Safety Communication. Safety review update of medications used to treat ADHD in children and young adults. 2011. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention>
10. US Food and Drug Administration. Drug Safety Communication. Safety review update of medications used to treat ADHD in adults. 2011. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0>
11. CredibleMeds®. <https://www.crediblemeds.org/>
12. Spencer T et al. Effects of atomoxetine on growth in children with attention deficit/Hyperactivity disorder following up to five years of treatment. *J Child Adolesc Psychopharmacol* 2007;17:689-700
13. Therapeutics Initiative. Atomoxetine for ADHD in children and adolescents. *Therapeutics Letter* 73. January-March 2009. <https://www.ti.ubc.ca/2009/03/31/atomoxetine-for-adhd-in-children-and-adolescents/>
14. Health Canada. Summary Safety Review. Methylphenidate Priapism. 2015. <https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?linkID=SSR00032>
15. US Food and Drug Administration. Drug Safety Communication. Methylphenidate Priapism. 2013. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-rare-risk-long-lasting-erections-males-taking>
16. Pucci M et al. Drug-induced priapism. *Adverse Drug Reaction Bulletin*. June 2020.

GUANFACINE

1. Wolraich ML et al. American Academy of Pediatrics. Clinical Practice Guideline for the Diagnosis, Evaluation and Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents. *Pediatrics* 2019;144:e20192528
2. CADDRA Canadian ADHD Resource Alliance. 2020 Canadian ADHD Practice Guidelines. Edition 4.1. <https://www.caddra.ca/>
3. Health Canada Drug Product Database. Intuniv XR.
4. US Food and Drug Administration Database. Intuniv.
5. Cortese S. Pharmacologic Treatment of Attention Deficit Disorder. *N Engl J Med* 2020;383:1050-1056
6. Health Canada. Summary Basis of Decision. Intuniv XR. <https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00254>
7. Huss M et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. *Eur Child Adolesc Psychiatry*:2018:1283-1294